Wzrost rentowności i kruchość sektora technologicznego obciążają amerykańskie akcje

Macro Pressures and the Yield Surge

The US equity landscape is facing significant headwinds as long-term Treasury yields reach multi-decade highs [6, 7]. The 30-year yield recently hit an intraday peak of 5.621%, marking its highest level since June 2002, while the 10-year yield closed at 5.256% [7]. This surge in yields has directly impacted major indices, with the Dow Jones falling 0.3% to 51,349.92 points, the S&P 500 slipping 0.2% to 7,670.84 points, and the Nasdaq Composite dropping 0.1% to 26,797.54 points [7].

This tightening in the bond market is occurring alongside a cooling of consumer sentiment, as the US saw a third consecutive month of declining consumer confidence in September [7]. Furthermore, persistent inflation risks remain a primary driver of market caution; July 2026 inflation was recorded at 3.4%, which is roughly 1.5 percentage points higher than the 1.9% annual gain seen in the S&P Cotality Case-Shiller U.S. National Home Price Index.

The combination of rising rates and declining confidence suggests a fragile macro environment [7]. Small-cap stocks appear particularly vulnerable to these shifts, with the Russell 2000 lagging the S&P 500 by more than 9 percentage points in the third quarter and falling more than 4% during the month of September alone.

Technology Sector: Growth vs. Capital Intensity

While the technology sector has previously benefited from high-beta rallies, current data suggests a period of heightened fragility. The sector is navigating a complex tension between massive AI-driven demand and the extreme capital requirements needed to sustain it. For instance, OpenAI is reportedly targeting US$30 billion in new funding at a US$1.4 trillion valuation [18]. This scale of investment is underscored by a note from Bain suggesting that AI faces a "$6 trillion test" to justify the costs associated with data center expansion [19].

Growth within the sector remains uneven [7]. On one hand, infrastructure and software components show robust momentum:

• Palantir's U.S. commercial revenue has surged 149% year-over-year.
• Micron reported revenue of $41.46 billion, a 345.7% increase year-over-year, noting that DRAM and NAND demand continues to significantly exceed industry supply.
• Google's Cloud has surged 82% and maintains a $460 billion backlog [7].

On the other hand, high valuations and shifting margins are creating concern. Palantir carries a trailing P/E of 162, while AMD trades at 40x forward earnings compared to Nvidia's 25x. Additionally, Meta Platforms, Inc. saw its operating margin fall from 43% to 31% following $3.6 billion in legal and severance charges [7].

Insider Activity and Market Sentiment

A notable trend contributing to tech-sector fragility is recent insider selling. Over the last 14 days, multiple reports indicate significant divestment from major players; specifically, 5 to 6 individuals at Meta Platforms, Inc. sold a combined $51 million to $64 million of stock via open-market sales during a period where the share price fell 0.3% [12, 7].

This realized selling, combined with the massive capital requirements for AI scaling, suggests a cautious stance among those closest to these large-cap positions [19]. The environment is further complicated by potential regulatory and safety headwinds. OpenAI recently decided not to release its GPT-6.1 Astra model due to safety concerns, and there are ongoing discussions regarding the legal implications of "rogue AI agents" [15].

The broader IPO market also reflects this uncertainty. Oura recently shelved a $2.2 billion IPO despite an order book that was reportedly four times subscribed, citing general market uncertainty [1].

Specialized Momentum in Biotech and Energy

While broad equities and tech face pressure, certain specialized sectors are showing distinct directional trends. The biotechnology sector, particularly in oncology, is seeing high-conviction support. This is evidenced by Kodiak Sciences, which saw its stock rise nearly 178% to close at $89.92 after its Phase 3 DAYBREAK study met primary endpoints for Zenkuda and tabirafusp-ted. Additionally, AstraZeneca has committed $2 billion to Summit Therapeutics to facilitate a cancer drug collaboration.

Conversely, the energy sector appears more fragile. While Brent crude has settled near $96.16, WTI has dropped to $89.38 [7]. The sector has faced downward pressure from falling oil prices and heightened geopolitical tensions, including reports of Iranian forces striking 19 ships in the Strait of Hormuz over a two-night period.

What to watch

• US Inflation and Employment Data: Upcoming inflation indicators and government jobs reports will be critical in determining the future path of interest rates [7].
• Federal Reserve Policy: Markets are monitoring whether the Fed will delay interest rate hikes until the end of the year [7].
• Micron Fiscal Results: Investors are awaiting Micron's fiscal fourth-quarter results, with the fiscal Q1 outlook expected to be a primary mover.
• SEC Meeting: The SEC Small Business Capital Formation Advisory Committee meeting is scheduled for August 6, 2026, at 1 p.m. ET.
• ESMO Congress 2026: Taking place October 23-27, 2026, where Zai Lab Limited will present global data regarding zocilurtatug pelitecan (zoci).
• Zai Lab Investor Call: Scheduled for Friday, October 23, at 8:00 a.m. ET.